Response to letter to the editor of JBMR: sequential Osteoanabolic therapy for osteoporosis.

J Bone Miner Res

Department of Orthopedic Surgery, Division of Osteoporosis, Locomotive Syndrome, Joint Disease Center, Aichi Medical University, 1-1 Yazakokarimata, Nagakute, Aichi 480-1195, Japan.

Published: March 2025

Download full-text PDF

Source
http://dx.doi.org/10.1093/jbmr/zjaf034DOI Listing

Publication Analysis

Top Keywords

response letter
4
letter editor
4
editor jbmr
4
jbmr sequential
4
sequential osteoanabolic
4
osteoanabolic therapy
4
therapy osteoporosis
4
response
1
editor
1
jbmr
1

Similar Publications

Post-Bariatric Hypoglycemia After Gastric Bypass: Clinical Characteristics, Risk Factors, and Future Directions-A Response to Grover et al.

Clin Endocrinol (Oxf)

March 2025

Department of Addiction Psychiatry, Taoyuan Psychiatric Center, Ministry of Health and Welfare, Taoyuan City, Taiwan.

Background: Post-bariatric hypoglycemia (PBH) after Roux-en-Y gastric bypass (RYGB) is a complex complication, often characterized by potentially severe hypoglycemic episodes and reduced hypoglycemia awareness. Recent findings suggest that autonomic dysfunction, preoperative hypoglycemia symptoms, and early dumping syndrome may each contribute to PBH risk.

Objective: To discuss critical insights from the recent study by Grover et al.

View Article and Find Full Text PDF

We commend the authors for their insightful study on inspiratory muscle training (IMT) in mechanically ventilated patients with difficult weaning, highlighting the robust use of maximum inspiratory pressure (MIP) as a key outcome. We suggest that a lower baseline maximum inspiratory pressure cutoff could better target patients with significant inspiratory dysfunction, improving the study's precision. Additionally, alternative imputation techniques, such as multiple imputation, could strengthen the handling of missing data.

View Article and Find Full Text PDF

While initial trials led to the accelerated approval of belantamab mafodotin, a BCMA-directed antibody-drug conjugate, confirmatory trials failed to establish benefit from this therapy for patients with relapsed refractory multiple myeloma (RRMM), eventually leading to its withdrawal from commercial use. With an imminent approval as an effective combination therapy, as seen in recent randomized trials, we report real-world clinical outcomes with belantamab mafodotin in 81 RRMM patients. With a median of 5 (range 2-15) prior lines of therapy, 92, 45, and 15% of the patients were triple-class refractory, penta-class refractory, and BCMA-refractory.

View Article and Find Full Text PDF

In this commentary, the authors respond to Ellaway & Patocka's "To define or not to define: A commentary on the Case for Metacognitive Reflection," which raised several thoughtful and discerning questions concerning the implications of defining, or alternatively, refraining from defining constructs. The authors advocate for navigating the liminal space between precision and flexibility, acknowledging the dynamic and permeable nature of conceptual boundaries while striving for clarity. Moreover, they emphasize that only after a boundary is described can the tensions, gaps, exceptions, and contradictions around that boundary be explored.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!